首页> 外文期刊>Japanese heart journal >Pyridinolcarbamate; Bradykinin Antagonist, in Patients Suffering from Arteriosclerosis Obliterans and Thromboangiitis Obliterans (Buerger's Disease)A Preliminary Report on the Treatment of Human Atherosclerosis
【24h】

Pyridinolcarbamate; Bradykinin Antagonist, in Patients Suffering from Arteriosclerosis Obliterans and Thromboangiitis Obliterans (Buerger's Disease)A Preliminary Report on the Treatment of Human Atherosclerosis

机译:吡啶醇氨基甲酸酯;缓激肽拮抗剂治疗闭塞性动脉硬化和闭塞性血栓性血管炎(Buerger病)的患者治疗人类动脉粥样硬化的初步报告

获取原文
           

摘要

Pyridinolcarbamate; Anginin (B23) is a venous bradykinin antagonist, which antagonizes competitively and reversibly the venoconstrictive effect of bradykinin and its active homologues. This compound has also been shown to antagonize the congestion, exudation and hemorrhage induced by brady-kinin and its active homologues and to remove the edematous change from experimental atheroma and to promote the normal fibrous healing of atheroma.This compound has also exhibited clinically a beneficial effect in the atherosclerotic diseases of the brain and the heart, however, the evaluation of the effectiveness of this kind of drug in these morbid conditions had to depend upon rather the indirect evidences. In order to see directly the effect of pyridinolcarbamate on the arterial lesion the atherosclerosis of extremities seems much more suitable. The authors have first attempted this compound in the treatment of atherosclerotic occlusion in lower extremities of 2 hos-pitalized patients; 33 years old and 57 years old men.The first patient aged 33 years suffered from a marked cyanosis of his right foot with a history of 6 months and the pulsations of right popliteal, posterior tibial and dorsal pedal arteries were completely absent and arterio-graphy revealed the complete obstruction of popliteal artery immediately above the knee joint. Pyridinolcarbamate was given 1Gm. daily and on the 3rd day of the medication the cyanosis disappeared dramatically and the intermittent claudication exhibited a slight improvement. On the 14th day of the medication the right dorsal pedal pulsation was recognized and on the 15th day the pulsation became visible through the skin and at the same time the pulsation of right popliteal artery began to be recognized. The volume of pulsation increased gradually but relatively rapidly and concomi-tantly with the remarkable improvement of intermittent claudication and on the 25th day of the treatment there was no differnce of skin temperature be-tween right and left foot and the pulsation exhibited almost normal volume in dorsal pedal artery. On the 26th day the pulsation of his right posterior tibial artery also reappeared. Under the medication of this compound no relapse and no untoward effects of the drug have been noted for 3 months period of the observation.The second case aged 57 years suffered from intermittent claudication and the absence of the pulsation of bilateral popliteal, dorsal pedal and pos-terior tibial arteries and the arteriography revealed the occlusion of the middle part of the right femoral artery.The treatment with pyridinolcarbamate for 2 weeks in a daily dose of one Gm. induced a slight improvement of intermittent claudication and on the end of third week a marked improvement was noted and at the same time the pulsation of his right dorsal pedal artery reappeared. His inter-mittent claudication exhibited a marked improvement concomitantly with the appearance of his dorsal pedal artery. A definite shortening in crest time in plethysmogram was noted in the bilateral second toes on the 130th day of the treatment. Thereafter his condition has been continuously good and he had no relapse and no untoward effects of the drug during the whole observation period of 5 months.The effect of pyridinolcarbamate seems to originate from the improve-ment of atheromatous changes by the compound in these patients.
机译:吡啶醇氨基甲酸酯; Anginin(B23)是一种静脉缓激肽拮抗剂,可竞争性和可逆性拮抗缓激肽及其活性同系物的静脉收缩作用。还显示出该化合物可拮抗缓激肽及其活性同源物引起的充血,渗出和出血,并消除实验性动脉粥样硬化的水肿变化并促进动脉粥样硬化的正常纤维愈合。该化合物在临床上也显示出有益的作用然而,在脑部和心脏的动脉粥样硬化性疾病中,这种药物的作用必须基于间接证据来评估。为了直接看到吡啶醇氨基甲酸酯对动脉病变的作用,四肢的动脉粥样硬化似乎更合适。作者首先尝试使用该化合物治疗2例住院患者的下肢动脉粥样硬化闭塞症。 33岁和57岁的男性。首例33岁的患者右脚出现明显发with,病史为6个月,完全没有右pop,后胫骨和后脚掌动脉搏动,并进行了动脉造影在膝盖关节上方发现动脉完全阻塞。给予吡啶醇氨基甲酸酯1Gm。每天和用药的第三天,紫osis急剧消失,间歇性lau行表现出轻微改善。在用药的第14天,可以识别到右背脚踏板的搏动,而在第15天,可以通过皮肤看到该搏动,同时开始可以识别出右lite动脉的搏动。随着间歇性lau行的明显改善,搏动的量逐渐增加,但相对较快,同时在治疗的第25天,左右脚之间的皮肤温度没有差异,并且搏动的体积几乎是正常的。脚背动脉。在第26天,右胫后动脉的搏动也重新出现。在该化合物的药物治疗下,观察到的3个月内未见复发,未见不良反应。第二例57岁,患有间歇性c行,无双侧pop肌,背侧踏板和正弦的搏动。胫骨前动脉和动脉造影显示右股动脉中部闭塞。使用吡啶环氨基甲酸酯治疗2周,日剂量为1 Gm。引起间歇性lau行的轻微改善,并在第三周结束时出现明显改善,与此同时,他的右背脚踏板动脉的搏动又出现了。他的间歇性lau行伴随他的脚背动脉的出现而显示出明显的改善。在治疗的第130天,双侧第二脚趾的体积描记图上的波峰时间明显缩短。此后,他的病情一直持续良好,在整个5个月的观察期内,他都没有复发,也没有药物的不良作用。吡啶吡啶氨基甲酸酯的作用似乎源于这些患者对化合物的动脉粥样硬化改变的改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号